Gilead's remdesivir fails to show benefit in European trial; no fetus risk seen with first trimester vaccination

The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review. Two promising drugs for COVID-19 fail to deliver. Two drugs that looked like promising treatments for COVID-19 in preliminary studies - remdesivir for hospitalized patients and camostat for patients who are not seriously ill - failed to show a benefit in those groups in randomized controlled trials, researchers reported in two separate papers.